Fenofibrate: Nursing Drug Guide, Statin Myopathy & NCLEX Review
Fenofibrate lowers triglycerides and improves lipid profiles in selected adults with high blood cholesterol or mixed dyslipidemia, but bedside safety hinges on myopathy and rhabdomyolysisβespecially with concurrent statins or renal impairment. Verify gallbladder and liver status, give with meals, and escalate promptly for muscle symptoms, new jaundice, or rising CK.
Fenofibrate may cause myopathy and rhabdomyolysis, particularly with impaired renal function or combined HMG-CoA reductase inhibitor therapy. Labeling also warns of serious drug-induced liver injury and cholelithiasis. Hold and escalate for new muscle pain, muscle weakness, dark urine, or biliary-type abdominal pain before progression to acute kidney injury.
π Contents
β‘ Quick facts
π‘ Key takeaway
Before every dose: confirm renal function supports therapy, screen for statin co-therapy unless benefit clearly outweighs risk, and ask about muscle or biliary symptoms. High-risk patients include older adults, those with chronic kidney disease, preexisting gallbladder disease, and concurrent warfarin or statin therapy.
Most common brand names
Fenofibrate is the generic name used in medication orders. Formulations include micronized capsules and film-coated tablets; bioavailability differs by formulationβverify the specific product in the MAR.
Common brands: Tricor, Antara, Lipofen, Fenoglide, Triglide. Confirm capsule strength (for example 67 mg, 134 mg, 200 mg micronized capsules) to prevent dose-selection errors.
Why we give it β Indications
Fenofibrate is adjunctive therapy to diet for adults with primary hypercholesterolemia, mixed dyslipidemia, or hypertriglyceridemia when diet and lifestyle changes alone are inadequate. Nurses pair lipid goals with safety surveillance because fibrates carry muscle, hepatic, renal, and gallbladder risks distinct from statin-only regimens.
| Use | Nursing relevance |
|---|---|
| Primary hypercholesterolemia / mixed dyslipidemia | Lowers LDL-C, total cholesterol, triglycerides, and apo B with diet restriction in saturated fat and cholesterol |
| Hypertriglyceridemia | Used when triglycerides remain elevated despite lifestyle measures; monitor for LDL rise in some Type IV/V patterns |
| Cardiovascular risk context | Often part of broader lipid plans in patients with atherosclerosis or prior heart attackβcoordinate with prescriber lipid strategy |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPAR-Ξ±), increasing lipolysis of triglyceride-rich particles, reducing apoprotein C-III, and shifting LDL particles toward larger, more rapidly cleared forms. Active metabolite fenofibric acid is highly protein bound. Nurses track response on periodic lipid panel trends and monitor for muscle, liver, renal, and biliary adverse effects.
Dosing overview
Give fenofibrate capsules (micronized) with meals to optimize absorption. Place patients on an appropriate lipid-lowering diet before and during therapy. Repeat lipid determinations at 4 to 8 week intervals when adjusting dose. Maximum dose is 200 mg per day. Withdraw therapy if adequate response is not achieved after two months at maximum dose.
Before you give it β Safety check
Pretreatment checks
- Confirm lipid indication, diet adherence, and prescriber lipid targets
- Review baseline liver function tests, renal function (serum creatinine / estimated clearance), and gallbladder history
- Screen medication list for concurrent HMG-CoA reductase inhibitors (for example simvastatin), coumarin anticoagulants, bile acid sequestrants, and hypoglycemic agents
- Ask about prior fibrate or statin muscle intolerance and untreated hypothyroidism
Contraindications (DailyMed)
- Hypersensitivity to fenofibrate
- Hepatic or severe renal dysfunction, including primary biliary cirrhosis
- Unexplained persistent liver function abnormality
- Preexisting gallbladder disease
Important interactions
| Drug / factor | Risk | Nursing action |
|---|---|---|
| HMG-CoA reductase inhibitors (statins) | Combined use associated with rhabdomyolysis, marked CK elevation, and acute renal failure in case reports; labeling recommends avoiding combination unless benefit clearly outweighs risk | Hold and escalate new muscle symptoms; involve pharmacy before continuing both agents |
| Coumarin anticoagulants | Potentiation with prolonged prothrombin time/INR and bleeding risk | Coordinate frequent INR monitoring until stable; document dose adjustments |
| Bile acid sequestrants | May bind fenofibrate and reduce absorption | Separate administration by at least 1 hour before or 4 to 6 hours after resin |
| Pravastatin / fluvastatin | Pharmacokinetic interactions vary; pravastatin exposure may increase with fenofibrate | Reinforce symptom reporting and avoid casual dual therapy without prescriber plan |
| Glimepiride | Labeling reports increased glimepiride AUC with fenofibrate | Monitor glucose when hypoglycemic agents are co-administered |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral capsule or tablet with meals at a consistent time each day.
- Verify formulation (micronized capsule vs tablet) and strength before administration
- Confirm meal timingβabsorption increases when taken with food
- Reconcile home lipid agents at admission to avoid duplicate fibrate or statin therapy
- Separate bile acid resin doses per labeling interval when both are prescribed
Safety in pregnancy has not been established; use only if potential benefit justifies potential fetal risk. Because excretion into human milk is not known and serious infant reactions are possible, decide with the care team whether to discontinue nursing or fenofibrate based on maternal treatment need.
Expected therapeutic response
- Improved LDL-C, total cholesterol, triglycerides, and HDL-C on follow-up lipid testing (timing individualized at 4 to 8 weeks)
- Triglyceride reduction in hypertriglyceridemia populations; be aware LDL may rise in some Type IV/V patterns
- Stable hepatic and renal markers without progressive symptoms
- No new muscle, biliary, or hepatic complaints requiring therapy interruption
Red flags β Stop and act
Pause dose and escalate promptly when symptoms suggest rhabdomyolysis, serious hepatotoxicity, or acute biliary complications.
- Diffuse myalgias, muscle tenderness or weakness, or marked CK elevationβespecially with malaise or fever
- Dark urine, abnormal stool, jaundice, pruritus, or persistent abdominal pain suggesting drug-induced liver injury
- ALT or AST greater than 3 times the upper limit of normal, particularly with bilirubin elevation
- Suspected cholelithiasis with right upper quadrant painβobtain gallbladder evaluation and discontinue if stones confirmed
Adverse effects
| Adverse effect | Clinical context | Nursing response |
|---|---|---|
| Abnormal liver function tests | Reported in trials; transaminase increases may be dose related; liver test abnormalities were a leading discontinuation reason | Trend ALT/AST; discontinue per labeling if persistent elevation or injury signs develop |
| Increased CK | Observed in clinical trials; assess when muscle symptoms reported | Hold fenofibrate if CK markedly elevated or myopathy diagnosed |
| Myopathy / rhabdomyolysis | May occur with fibrate monotherapy; higher concern with renal impairment and statin co-therapy | Hold dose, notify prescriber/pharmacist, trend CK and renal function |
| Cholelithiasis | Fibrate class may increase biliary cholesterol excretion | Evaluate gallbladder if biliary symptoms; discontinue if gallstones found |
| GI symptoms | Abdominal pain, diarrhea, nausea reported | Supportive care; differentiate from hepatobiliary red flags |
| Respiratory disorder / rhinitis | Listed among common trial adverse events | Document and correlate with infection vs drug intolerance as clinically appropriate |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
There is no specific treatment for fenofibrate overdose. General supportive care is indicated, including vital sign monitoring and clinical observation.
Labeling guidance
- No specific antidote for fenofibrate overdose
- Consider emesis or gastric lavage for unabsorbed drug when indicated, maintaining airway protection
- Hemodialysis is not recommended because fenofibrate is highly protein bound
- Escalate through local toxicology services and emergency pathways per facility protocol
Look-alike / sound-alike and error prevention
- Fenofibrate vs fenofibric acid β active metabolite name confusion in orders and documentation
- Fenofibrate vs gemfibrozil β both fibrates with overlapping but not identical risk profiles; verify intended agent
- Micronized capsule strength mix-ups β 67 mg, 134 mg (as multiple 67 mg), and 200 mg regimens are not interchangeable without prescriber review
- Fibrate plus statin duplication β common reconciliation error after admission; confirm whether combination is intentional and approved
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Meal-linked administration | Coordinate fenofibrate with meals; document if dose held because patient is NPO |
| Statin combination screen | Flag concurrent statin on MAR and verify prescriber intent before each dose |
| Muscle symptom interview | Ask about diffuse pain, tenderness, weakness, and functional decline in high-risk patients |
| Biliary symptom screen | Assess for postprandial RUQ pain or nausea suggesting cholelithiasis |
| INR coordination | When warfarin is co-prescribed, confirm INR monitoring plan is current |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Labeling limits initial dose to 67 mg daily; proactive symptom checks reduce delayed reporting |
| Mild to moderate renal impairment | Start 67 mg daily; avoid use in severe impairment (CrCl β€ 30 mL/min) |
| Statin co-therapy | Highest priority interactionβavoid unless benefit clearly outweighs risk |
| Gallbladder disease history | Contraindicated with preexisting gallbladder disease; monitor new biliary symptoms closely |
| Anticoagulated patients | Increased bleeding risk with coumarin anticoagulants; frequent INR until stable |
| Pregnancy / lactation | Use in pregnancy only if benefit justifies risk; weigh nursing vs therapy need |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Lipid panel at baseline and every 4 to 8 weeks when adjusting dose; discontinue if inadequate response after two months at 200 mg daily
- Liver function (ALT, AST, total bilirubin) at baseline and periodically during therapy
- CK when patients report unexplained muscle pain, tenderness, weakness, or malaise with fever
- Renal function before initiation and when increasing dose in impaired renal function or elderly patients
- INR frequently when coumarin anticoagulants are co-prescribed until stable
| Priority lab / vital trend | Use in fenofibrate safety workflow |
|---|---|
| Lipid panel | Documents therapeutic response and guides dose changes at 4 to 8 week intervals |
| Liver function tests (ALT, AST, bilirubin) | Detect hepatotoxicity; discontinue if ALT/AST > 3Γ ULN or with injury symptoms |
| CK (creatine phosphokinase) | Assess when myopathy suspected; discontinue if markedly elevated or myopathy diagnosed |
| Serum creatinine | Supports renal dosing decisions and monitors injury when rhabdomyolysis is suspected |
On a small screen, swipe or scroll sideways to see the full table.
Document
- Whether dose was given with food and exact capsule strength administered
- Statin and anticoagulant co-therapy review with pharmacy input when applicable
- Hold actions, CK/hepatic trends, and prescriber notifications
- Patient teach-back on muscle, urine, and jaundice warning signs
Patient teaching
- Take fenofibrate with meals as directed; do not crush or open capsules unless product labeling allows
- Report promptly any unexplained muscle pain, tenderness, weakness, dark urine, yellowing skin or eyes, or persistent abdominal pain
- Tell clinicians about all new medicationsβincluding statinsβbefore restarting therapy
- Contact the care team if pregnancy is recognized or if breastfeeding is planned
- Keep scheduled blood tests for lipids, liver enzymes, and INR when anticoagulated
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Hypersensitivity, hepatic or severe renal dysfunction, unexplained persistent LFT abnormality, or preexisting gallbladder disease is present
- New diffuse myalgias, muscle tenderness or weakness, or markedly elevated CK
- Signs of drug-induced liver injury or ALT/AST > 3Γ ULN (especially with bilirubin rise)
- Suspected or confirmed gallstones on evaluation for cholelithiasis
- Concurrent statin therapy without documented risk-benefit approval and monitoring plan
- Pregnancy recognized without prescriber risk-benefit plan
Hold parameters can vary by institution. Follow prescriber orders, pharmacy guidance, and local policy.
Clinical practice integration and workflow
Fenofibrate errors often involve giving without meals, missing statin co-therapy risk, or under-recognizing early muscle or hepatobiliary toxicity. Build a workflow that pairs lipid monitoring with renal, hepatic, and interaction surveillance.
1. Check-before-you-give protocol
- Verify formulation, strength, and meal availability
- Confirm renal function supports current dose (67 mg start vs 200 mg maintenance)
- Screen for statin and warfarin co-therapy with pharmacy when present
- Ask focused muscle and hepatobiliary symptom questions before administration
2. High-alert and safety badge
Statin combination & rhabdomyolysis risk β hold and escalate on muscle cuesFibrate monotherapy can cause myopathy, but combined statin therapy is the highest-stakes interaction. Treat new diffuse muscle symptoms as a medication safety event until CK and renal trends are reviewed.
3. Clinical workflow: hold and question rules
- If statin is added without documented approval, hold fenofibrate and clarify lipid plan with prescriber/pharmacist
- If CK rises with muscle symptoms, discontinue fenofibrate and escalate for rhabdomyolysis pathway
- If cholelithiasis is suspected, obtain gallbladder studies and discontinue if stones are confirmed
4. Critical teach-back questions
- βWhy must you take this medication with food?β (Patient should link absorption and routine meal timing.)
- βWhat symptoms mean you should call before the next dose?β (Patient should include muscle pain/weakness, dark urine, jaundice, and persistent abdominal pain.)
5. Care coordination
Pharmacist: Interaction stratification, dose optimization, and escalation thresholds for muscle toxicity
Prescriber / cardiology / primary team: Ongoing lipid strategy, adverse event decision-making, and post-hold rechallenge planning
π§ Quick mental checklist
- Was the last dose given with a meal, and is the patient NPO now?
- Is a statin still on the MAR without a documented combination plan?
- Any new muscle, urine, jaundice, or RUQ pain symptoms today?
- Are liver enzymes, CK, and creatinine trends current when symptoms exist?
- Is INR monitoring up to date if warfarin is co-prescribed?
Fenofibrate NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for fenofibrate using a tabbed case panel (MAR, labs, history, nursing notes), then priority action, SATA cue recognition, trend interpretation, ordered response, matrix urgency judgment, and overdose clozeβfocused on statin combination myopathy, hepatotoxicity, and renal dosing safety.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Fenofibrate 200 mg PO with dinner (held yesterday for NPO procedure)
- Simvastatin 40 mg PO at bedtime β started 10 days ago
- Metformin 1000 mg PO twice daily
- Warfarin 5 mg PO daily β INR follow-up due
- Admission: CK 168 U/L, creatinine 1.3 mg/dL, ALT 32 U/L, triglycerides 410 mg/dL
- Day 7: CK 420 U/L, creatinine 1.4 mg/dL
- Today: CK 1620 U/L, creatinine 1.8 mg/dL, AST 78 U/L, ALT 74 U/L
- Urinalysis: large blood, few RBCs
- 58-year-old with type 2 diabetes and mixed dyslipidemia on chronic fenofibrate
- Estimated CrCl 48 mL/min (moderate renal impairment)
- Simvastatin added on discharge 10 days ago for LDL goal
- No prior documented fibrate myopathy
- Reports bilateral thigh aching and difficulty standing from chair
- Urine βtea-coloredβ since morning; denies dysuria
- Still eating dinner tray; fenofibrate due with meal in 30 minutes
- States βI thought more cholesterol pills would help fasterβ
Answer key & rationale
Frequently asked questions
Why is fenofibrate plus a statin a high-priority nursing check?
Labeling recommends avoiding combined HMG-CoA reductase inhibitor therapy unless benefit clearly outweighs risk because case reports link the combination to rhabdomyolysis and acute renal failure. Hold and escalate new muscle symptoms immediately.
When must fenofibrate be given with food?
Micronized fenofibrate labeling instructs administration with meals to optimize bioavailability. If a patient is NPO, clarify hold parameters with the prescriber rather than giving without a meal plan.
What renal dosing rules apply to fenofibrate?
Avoid use in severe renal impairment (CrCl 30 mL/min or less). Start 67 mg daily in mild to moderate impairment or in the elderly, increasing only after renal and lipid review.
What gallbladder-related action does labeling require?
If cholelithiasis is suspected, obtain gallbladder studies and discontinue fenofibrate if gallstones are found. Preexisting gallbladder disease is contraindicated.
Is there an antidote for fenofibrate overdose?
No specific treatment exists. Supportive care is indicated; hemodialysis is not recommended because the drug is highly protein bound.
Which labs should nurses track most closely?
Lipids every 4 to 8 weeks when adjusting dose, liver enzymes at baseline and periodically, CK when muscle symptoms appear, and creatinine for renal dosing and rhabdomyolysis surveillance.
References
- U.S. National Library of Medicine. Fenofibrate capsule (micronized) β Full prescribing information. DailyMed (Rhodes Pharmaceuticals LLC label, set ID 829f5c2e-3329-4644-bccb-267afb678540).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=829f5c2e-3329-4644-bccb-267afb678540
- U.S. Food and Drug Administration. MedWatch: FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
- American Heart Association. About cholesterol.https://www.heart.org/en/health-topics/cholesterol/about-cholesterol
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.